

## COMMENTS AND RESPONSES

### **Gestational Diabetes Mellitus: NICE for the U.S.? A Comparison of the American Diabetes Association and the American College of Obstetricians and Gynecologists Guidelines With the U.K. National Institute for Health and Clinical Excellence Guidelines**

Response to Holt et al.

Holt et al. (1) acknowledge the cost-effectiveness of the American Diabetes Association (ADA) criteria, which are similar to our recommendation of offering all women a glucose test. They have understated the importance of the article by Landon et al. (2), which showed that active management of gestational diabetes mellitus (GDM) not only led to significant reductions in neonatal size/fat mass (which may predict future diabetes/obesity in the offspring), but also significant reductions in shoulder dystocia (1.5 vs. 4.0%), cesarean delivery (26.9 vs. 33.8%), and preeclampsia/gestational hypertension (8.6 vs. 13.6%). These findings make screening for GDM even more cost-effective.

When women who are below ADA weight criteria are excluded from screening, 10% of GDM is missed, including 16% with hyperglycemia warranting insulin therapy (3). Because 80% of low-risk pregnant women needed to be tested using ADA criteria in slimmer times, the importance of keeping systems simple to maximize implementation (as implied by the postnatal testing regimen by Holt et al.) suggests universal screening would be best during pregnancy (4). The limita-

tions of the health economic model (e.g., it excludes benefits from a more simple implementation approach and future impact) require policy implementation to take a broader view. Although some may accept the National Institute for Health and Clinical Excellence (NICE) approach, philosophically, we, and probably many others, remain committed to supporting women to choose their screening method.

We agree that the screening timing for undiagnosed preexisting diabetes remains unresolved. The International Association of Diabetes and Pregnancy Study Groups has recently recommended screening "as early as possible" (5). The NICE recommendations advise screening at 16–18 weeks, which is not early and potentially allows the growing fetus to be exposed to significant hyperglycemia for many weeks.

We remain bemused at basing national policy on one study with a relatively small number of subjects and ignoring all the other published evidence. Our references (6) provide other evidence: up to 56% of women with diabetes postnatally would be missed using fasting glucose alone. To dismiss the importance of identifying impaired glucose tolerance with its high risk of progression (preventable in some women) could be seen as inappropriate. We do applaud the 100% follow-up of women for postnatal testing, a figure rarely achieved in any health activity. However, as the key difficulty in a glucose tolerance test is attending fasting, perhaps the optimal approach, again consistent with our philosophy of patient empowerment, is to offer women, in an informed way, the option of either test and to allow the woman to make the choice. Finally, the suggested use of A1C for screening postnatally may be inappropriate because of altered red cell dynamics and the potential for anemia during the postnatal period.

DAVID SIMMONS, MD<sup>1</sup>  
AIDAN McELDUFF, FRACP<sup>2</sup>  
HAROLD DAVID MCINTYRE, FRACP<sup>3</sup>  
MOHAMED ELRISHI, MRCP<sup>4</sup>

From the <sup>1</sup>Institute of Metabolic Science, Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K.; the <sup>2</sup>Northern Sydney Endocrine Centre, St Leonards, New South Wales, Australia; the <sup>3</sup>University of Queensland and Mater Health Services South Brisbane, Queensland, Australia; and the <sup>4</sup>Department of

Diabetes, Princess Alexandra Hospital NHS Trust, Essex, U.K.

Corresponding author: David Simmons, david.simmons@addenbrookes.nhs.uk.

DOI: 10.2337/dc09-2335

© 2010 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

**Acknowledgments**—No potential conflicts of interest relevant to this article were reported.

#### References

- Holt RIG, Jacklin PB, Round JA, Muggleston MA, Hughes RG. Gestational diabetes mellitus: NICE for the U.S.? A comparison of the American Diabetes Association and the American College of Obstetricians and Gynecologists guidelines with the U.K. National Institute for Health and Clinical Excellence guidelines: response to Simmons et al. (Letter). *Diabetes Care* 2010; 33:e46. DOI: 10.2337/dc09-2234
- Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp JM Jr, Sciscione A, Catalano P, Harper M, Saade G, Lain KY, Sorokin Y, Peaceman AM, Tolosa JE, Anderson GB, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. *N Engl J Med* 2009;361:1339–1348
- Moses RG, Moses J, Davis WS. Gestational diabetes mellitus: do lean young Caucasian women need to be tested? *Diabetes Care* 1998;21:1803–1806
- Simmons D, Devers MC, Wolmarans L, Johnson E. Difficulties in the use of risk factors to screen for gestational diabetes mellitus (Letter). *Diabetes Care* 2009; 32:e8. DOI: 10.2337/dc08-1313
- International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010;33:676–682
- Simmons D, McElduff A, McIntyre HD, Elrishi M. Gestational diabetes mellitus: NICE for the U.S.? A comparison of the American Diabetes Association and the American College of Obstetricians and Gynecologists guidelines with the U.K. National Institute for Health and Clinical Excellence guidelines. *Diabetes Care* 2010;33:34–37